Post Marketing Study on Pluvicto in Korea

Novartis

Status: Enrolling

Conditions: Metastatic Castration-resistant Prostate Cancer

Treatments: Other: Lutetium vipivotide tetraxetan

Study type: Observational

Funder types: Industry

Identifiers

NCT06514521

CAAA617A1KR01

Details and patient eligibility

About

Post marketing study on Pluvicto in Korea

Full description

This is open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Pluvicto in patients with mCRPC in the real-world setting in South Korea.

Enrollment: 278 estimated patients

Sex: Male

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

Study participants eligible for inclusion in this study must meet all of the following criteria:

1. Male adult patient age ≥ 18
2. Subject who are being treated with Pluvicto or whose treatment plan is finalized and scheduled to be administered at the time of consent by physician in accordance with the approved indication in South Korea
3. Subject who provided the written informed consent prior to the study enrollment

Exclusion criteria

Study participants meeting any of the following criteria are not eligible for inclusion in this study:

1. Subject whose medical record is not accessible
2. Subject who is not willing to provide the informed consent

Trial design

278 participants in 1 patient group

Lutetium vipivotide tetraxetan

Description:

Patients prescribed with Lutetium vipivotide tetraxetan in real world practice

Treatment:

Other: Lutetium vipivotide tetraxetan